^
9d
Human Papillomavirus Infection and Cervical Cytology Among Vulnerable Women in Rome, Italy. (PubMed, J Clin Med)
Only 29 of the 77 women who had heard of HPV (37.7%) knew of the HPV vaccine, and only 2 had been vaccinated in the entire study group (1.5%). Tailored preventive strategies and comprehensive information campaigns should be developed and implemented to enhance awareness of HPV infection and actively promote vaccination among women in vulnerable groups.
Journal
|
Xpert HPV Assay
16d
Trial completion
|
Xpert HPV Assay
2ms
The Women's Screening and Self-Testing Program (PROMETA) Study (clinicaltrials.gov)
P=N/A, N=8445, Not yet recruiting, Tulane University | Trial completion date: Jan 2031 --> Aug 2028 | Trial primary completion date: Jan 2031 --> Jun 2028
Trial completion date • Trial primary completion date
|
Xpert HPV Assay
2ms
Prevalence and age-related trends of high-risk Human Papillomavirus genomes in Ecuadorian women: a comprehensive cross-sectional study. (PubMed, BMC Infect Dis)
The study provides a more nuanced understanding of HPV prevalence in Ecuador, indicating that HPV rates are lower than previous national studies but higher than global estimates. The results lay essential groundwork for targeted public health interventions and suggest the need for future research to address methodological limitations.
Observational data • Journal
|
Xpert HPV Assay
2ms
New trial
|
Xpert HPV Assay
3ms
Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries (clinicaltrials.gov)
P=N/A, N=1002, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Jul 2026 --> Jul 2025
Trial primary completion date
|
Xpert HPV Assay
3ms
Increased proportion of "other hrHPV" genotypes other than 16 and 18/45 among women attending ART clinic in Northern Uganda. (PubMed, Gynecol Oncol Rep)
Unemployment was associated with increased odds of hrHPV among the study participants. This calls for extended HPV genotyping during screening and customization of HPV vaccination to cover all HPV genotypes.
Journal
|
Xpert HPV Assay
4ms
HPV testing in cervical cancer formalin-fixed paraffin embedded tissues: Reliability of the Xpert HPV test and high-risk HPV genotypes distribution in Tunisia. (PubMed, PLoS One)
This study demonstrated a high accuracy of the Xpert-HPV test for HR-HPVs detection and genotyping in FFPE CC tissues and revealed a distinct distribution of HR-HPVs in Tunisia.
Journal
|
Xpert HPV Assay
5ms
High-risk HPV infection and the risk of preterm birth in a Romanian tertiary maternity cohort: a prospective observational study. (PubMed, J Med Life)
Although genotype-specific risks require confirmation, the data align with emerging evidence that HPV infection itself-not only post-treatment cervical changes-may promote spontaneous PTB. If corroborated, these findings extend the public-health value of HPV vaccination beyond cancer prevention and support closer obstetric surveillance of hr-HPV-positive pregnancies.
Observational data • Journal
|
Xpert HPV Assay
5ms
Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries (clinicaltrials.gov)
P=N/A, N=1002, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting
Enrollment closed
|
Xpert HPV Assay
9ms
Improving the Sensitivity-Specificity Balance of Human Papillomavirus Testing on Self- and Clinician-Collected Samples in South Africa. (PubMed, JCO Glob Oncol)
Using more stringent Ct cutoffs on the three channels that detect the eight highest-risk HPV types can improve the sensitivity-specificity balance of a round of screening in both self- and clinician-collected samples. Although performance of HPV testing on self-collected samples is excellent, performance parameters are better on clinician-collected samples.
Journal
|
Xpert HPV Assay
10ms
Evaluating the performance of the Xpert HPV Assay in detecting HPV positive cases in Morocco. (PubMed, Tumour Virus Res)
Its integration into primary cervical cancer screening programs could significantly enhance the early detection of HPV-positive cases, thereby strengthening the screening framework and potentially reducing both the incidence and mortality of cervical cancer. Future studies should focus on confirming these results and exploring the utility of this method in conjunction with other diagnostic tools such as visual inspection with acetic acid (VIA) for a comprehensive assessment of its effectiveness in real-world settings.
Journal
|
Xpert HPV Assay